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Abstract
Background: Gastric cancer is the second highest cause of global cancer mortality. To explore the complete
repertoire of somatic alterations in gastric cancer, we combined massively parallel short read and DNA paired-end
tag sequencing to present the first whole-genome analysis of two gastric adenocarcinomas, one with
chromosomal instability and the other with microsatellite instability.
Results: Integrative analysis and de novo assemblies revealed the architecture of a wild-type KRAS amplification, a
common driver event in gastric cancer. We discovered three distinct mutational signatures in gastric cancer -
against a genome-wide backdrop of oxidative and microsatellite instability-related mutational signatures, we
identified the first exome-specific mutational signature. Further characterization of the impact of these signatures
by combining sequencing data from 40 complete gastric cancer exomes and targeted screening of an additional
94 independent gastric tumors uncovered ACVR2A, RPL22 and LMAN1 as recurrently mutated genes in microsatellite
instability-positive gastric cancer and PAPPA as a recurrently mutated gene in TP53 wild-type gastric cancer.
Conclusions: These results highlight how whole-genome cancer sequencing can uncover information relevant to
tissue-specific carcinogenesis that would otherwise be missed from exome-sequencing data.
Background
Gastric cancer (GC) is the fourth most common cancer
and the second leading cause of cancer death worldwide.
Early stage GC is often asymptomatic or associated with
non-specific symptoms, resulting in most patients pre-
senting at advanced disease stages. Treatment options
for late-stage GC patients are limited, with surgery and
chemotherapy regimens offering modest survival bene-
fits. Environmental risk factors for GC include a high
salt diet, smoking, and infection by Helicobacter pylori
[1]. Understanding the mutational impact of these envir-
onmental exposures on the genomes of gastric epithelial
cells is essential to shed light on specific genes and
pathways associated with gastric tumorigenesis.
Previous studies in lung cancer [2,3], melanoma [4],
and leukemia [5] have shown that environmental carci-
nogens and drugs can elicit specific somatic mutational
profiles in cancer genomes, referred to as ‘mutational
signatures’. While previous studies on GC have applied
exome-sequencing approaches to identify frequently
mutated genes [6,7], identifying mutational signatures is
best done using whole-genome data, due to its comple-
teness and ability to simultaneously uncover micro- and
macro-scale somatic alterations. In this study, we sought
to provide a more comprehensive understanding of
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mutational processes in GC by analyzing whole-genome
sequences of two GCs and their matched-normal con-
trols, using both short-read (SR) next-generation
sequencing and a long insert (approximately 10 kbp)
DNA paired-end tag (DNA-PET) protocol [8]. We also
sought to explore the combination of these datasets for
de novo assembly of cancer and normal genomes and to
comprehensively catalogue a range of (point mutations
to megabase-sized) somatic alterations in the tumor.
Finally, we used this catalogue to characterize the
impact of mutational processes on genes and used a
screening approach to validate recurrently mutated
genes in subtypes of GC defined by specific mutational
processes.
Results
Integrative short read/DNA-PET analysis and de novo
assembly
The matched tumor and normal samples analyzed were
from two Singaporean patients. One GC exhibited evi-
dence of microsatellite instability (MSI) and active H.
pylori infection (see Table S1 in Additional file 1 for other
clinical characteristics). Each tumor and matched normal
sample was sequenced to more than 30-fold average base
pair coverage by Illumina SR sequencing (Materials and
methods; Table S2 in Additional file 1), and to > 130-fold
physical coverage using large-insert (approximately 10
kbp) DNA-PET sequencing [9] on the SOLiD platform
(Materials and methods; Table S3 and Note 1 in Addi-
tional file 1). Single nucleotide variants (SNVs) and short
insertions and deletions (indels) from tumor and normal
genomes were combined to identify somatic variants
(Table 1 and Materials and methods) and reliability of
somatic calls was confirmed using targeted sequencing
(validation rate of 90% for SNVs and 96% for indels; Mate-
rials and methods). SR and DNA-PET data were also used
to identify somatic copy-number variations (CNVs) and
structural variations (SVs) (validation rate = 81%; Materi-
als and methods; Note 1 in Additional file 1).
We integrated the SR and DNA-PET sequence informa-
tion to perform de novo assembly of the tumor and nor-
mal genomes. While complete de novo assembly of a
tumor genome still poses significant technical challenges
and has not been attempted before, we were able to use
the SR/DNA-PET data to construct highly contiguous
draft assemblies of median scaffold lengths (N50) in the
range of 41 to 148 kb, with DNA-PET data assisting in tri-
pling sequence contiguity of the assemblies (Materials and
methods; Note 2 and Table S5 in Additional file 1). Impor-
tantly, performing de novo SR/DNA-PET assembly
revealed several findings not observed using conventional
analyses of the SR data. First, the de novo approach
allowed for characterization of large-scale somatic struc-
tural variations at single base-pair resolution (SR libraries
were unable to identify nearly half of the validated SVs
and fusions genes; Note 1 in Additional file 1). For exam-
ple, NGCII092 exhibited a focal genomic amplification on
chromosome 12p11-12 in a region containing the wild-
type KRAS gene, a genomic event frequently observed in
GC [10]. The combined SR/DNA-PET data (Materials and
methods) enabled a detailed putative reconstruction of the
evolutionary lineage of the amplified KRAS locus with
concomitant deletion of a proposed tumor suppressor
gene RASSF8 (as well as another focal amplicon at chro-
mosome 6p) as described in the supplementary text
(Figure 1; Figures S1 and S2 and Note 3 in Additional file
1). Reconstruction of the tumor genomes also allowed the
prediction of fusion genes and complex rearrangements
that resemble patterns created by replication coupled
mechanisms [11] and are further described in the supple-
mentary text (Note 4 and Figures S3 and S4 in Additional
file 1 and Table S6 in Additional file 2).
Second, a combined SR/DNA-PET analysis allowed us
to assemble sequences present in the tumor genome but
not in the reference human genome. For example, in
patient NGCII082 exhibiting active H. pylori infection,
we detected approximately 2,000 short-sequence reads
and > 600 DNA-PET tags corresponding to the H. pylori
genome (the first such report for a bacterial pathogen
from tumor sequencing), in addition to a tumor-asso-
ciated microbiome (these were not seen in NGCII092;
see Figure S5 and Note 5 in Additional file 1 for details).
Note that, despite being fewer in number, the DNA-PET
Table 1 Somatic variations in two GC tumors identified
by whole genome sequencing approaches
Patient ID NGCII082 NGCII092
SNVs, all somatic 14,856 17,473
Coding regions 119 116
Non-synonymous 86 73
Promoter regions 101 161
Indels, all somatic 11,738 2,486
Coding regions 12 2
CNVs, all somatic 836 21,776
Affecting genes 3 265
SVs, all somatic 12 146
Affecting genes 11 96
Deletions 6 56
Tandem duplications 2 8
Unpaired inversions 0 26
Inversions 0 2
Insertions (intra-chromosomal) 0 0
Insertions (inter-chromosomal) 0 0
Isolated translocations 0 3
Balanced translocations 0 0
Complex events (intra- chromosomal) 4 49
Complex events (inter- chromosomal) 0 2
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Figure 1 Copy number of two gastric cancer genomes, mechanism of 12p amplification and creation of a fusion gene. (a) Somatic
CNVs in the two gastric tumors (chromosomes are arranged on the x-axis, copy number is shown on the y-axis). (b) Copy number of
chromosome 12 (top) and the amplicon on 12p (middle) are shown in orange (y-axis). Rearrangements identified by DNA-PET clusters with a
size ≥ 45 are represented by arrows and connecting lines (bottom). Dark red and pink arrows represent 5’ and 3’ cluster regions, respectively,
with the connection between the tip of the dark red and the blunt end of the pink arrows. Numbers represent cluster sizes. (c) Fusion between
SOX5 and OVCH1 predicted by a rearrangement point with cluster size of 129 in (b).
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tags contributed significantly to the physical coverage
and analysis of the genomes (Figure S5 and Note 5 in
Additional file 1).
Third, the de novo assembly enabled annotation of
human genes and variants in sequences absent in the
reference genome. In total, we identified more than 3 Mbp
of novel sequence (longer than 500 bp), containing several
genes (including an ortholog to a cytokine receptor-like
factor - CRLF2), and more than a 1,000 somatic and germ-
line variants for each patient (Materials and methods;
Note 2 and Table S5 in Additional file 1).
Mutational signatures of damage by reactive oxygen
species, deamination and microsatellite instability
We characterized mutational signatures in the GC gen-
omes based on 14,856 somatic SNVs (11,738 indels) in
NGCII082 and 17,473 somatic SNVs (2,486 indels) in
NGCII092 that were identified from the whole-genome
data (Table 1). This accounts for an average mutation fre-
quency of 5 per megabase and included > 100 SNVs in
protein coding regions for each tumor (Table 1; Note 6 in
Additional file 1). Note that we identified more than five
times the number of somatic variants uncovered in earlier
sequencing studies [6,7] that were restricted to exomes
(5,588 SNVs and 2,347 indels identified from 37 exomes),
highlighting the statistical advantage of whole-genome
analysis for studying mutational signatures. Overall,
NGCII082, an MSI-positive tumor, displayed an excess of
SNVs in protein coding regions (P-value < 0.02, c2 test)
and a striking seven-fold higher frequency of micro-indels
(Figures 2 and 3d) but a lack of large-scale SVs and ampli-
fications or deletions (Figure 2 and Table 1). In contrast,
NGCII092 exhibited a complex copy number profile of
extensive focal amplifications and deletions, and a mutated
TP53 gene, consistent with the presence of chromosomal
instability (CIN) in the tumor genome (Figure 2). These
results agree with the mutual exclusivity seen in MSI and
CIN pathways for inducing mutations in other cancers as
well [12].
The clear excess of micro-indels in the MSI-positive GC
(Figure 3d; Figure S10 in Additional file 1) was character-
ized by a pattern of single base-pair thymine deletions in
mononucleotide repeats (79%). In contrast, there were a
comparable number of insertions in both the MSI-positive
and CIN-positive GC, and a similar deletion-specific pat-
tern has also been noted before [13]. Also, non-thymine
and non-mononucleotide repeat deletions were not found
to be in excess. The correlation between MSI phenotype
and the specific deletion signature identified here was
further confirmed from previous exome-sequencing data
[7] (four MSI-positive exomes), though this aspect was not
noted in the previous work. In terms of genomic location,
the deletions were randomly scattered throughout the
genome and occurred in proportion to the regional
presence of thymine mononucleotide repeats (that is, 85%
of homopolymers > 5 bp). Thus, despite the bias towards
thymine deletions, there seems to be an absence of a tar-
geting mechanism on the genome for the MSI-associated
signature.
Despite exhibiting very different somatic alteration pat-
terns (MSI or CIN), the mutational frequencies of both
GCs at the single nucleotide level were highly similar,
being significantly biased towards C > A and T > A altera-
tions compared to normal genomes (P-value < 10-16, c2
test; Figure 3a). These alterations likely represent muta-
tions caused by reactive oxygen and nitrogen species (ROS
and RNS), which are known to produce C > A and T > A
mutations [14]. Also, a likely trigger is H. pylori infection,
which has been shown to cause chronic inflammation and
ROS/RNS production in gastric epithelial cells [14]. The
C > A mutations observed were associated with highly sig-
nificant sequence-selectivity, being marked by an excess at
CpCpT (NGCII082, odds ratio (OR) = 3.2, P-value < 10-16,
c2 test) or TpCpA sites (NGCII092, OR = 1.7, P-value <
10-16, c2 test) and extensions of these motifs (Materials
and methods; Note 6 and Figure S6 in Additional file 1
and Table S14 in Additional file 6). This pattern is distinct
from the C > A signature seen in smoking-associated
small-cell lung cancer where an excess was seen in CpG
dinucleotides outside CpG islands, suggesting a link with
methylation status [2,3]. Further work is required to iden-
tify the mechanistic basis of sequence selectivity in this
genome-wide GC-specific signature.
Exome-biased mutational signature in GC
Unlike the MSI and ROS/RNS signatures that were pre-
sent in coding and non-coding regions of the genome, we
also detected a third GC mutational signature only evident
in coding regions (Figure 3b), characterized by an excess
of C > T mutations. These mutations were in excess at
CpG (NGCII082, OR = 1.2, P-value < 10-16, c2 test) and
GpC site (NGCII092, OR = 1.4, P-value < 10-16, c2 test)
dinucleotides. The CpG alterations likely represent deami-
nation of methylated cytosines followed by errors asso-
ciated with transcription-coupled repair, which has also
been observed in other cancers [2,4]. However, the latter
bias towards C > T alterations occurring at GpC motifs
appears to be a unique feature not previously reported in
other cancers [2,4] and could represent deamination due
to enzymes such as AID (activation-induced cytidine dea-
minase) [15]. AID is known to preferentially target tran-
scribed regions [16] and is aberrantly activated due to H.
pylori infection in the gastric epithelium [17]. Taken col-
lectively, our whole-genome sequencing data implicates a
minimum of three mutational signatures present in GC
genomes, related to the presence of MSI, ROS/RNS, and
deamination processes.
To further characterize the mutational signatures, we re-
analyzed a total of 40 GC exomes, combining data from
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Figure 2 Map of somatic alterations in two gastric cancer genomes. The Circos plots depict the following information in order from outer
to inner rings: using WGS data (1) CNVs (gain in red capped at 10 copies and loss in gray), (2) indel density (indel frequency per 10 kbp in blue,
capped at 5 indels/10 kbp), (3) SNV density (SNV frequency per 10 kbp in black, each ring is 5 SNVs/10 kbp, capped at 10), and using DNA-PET
data, (4) deletions (in red), tandem duplications (green) and inversions (purple), (5) intra- and (6) inter-chromosomal, insertions (orange) and
unpaired SVs (gray).
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earlier studies [6,7] with two new exomes in this study
(Materials and methods; Table S8 and Figure S7 in Addi-
tional file 1). Specifically, a comparison of somatic and
germline frequencies for the exomes showed that all but
one patient had a significant excess of C > A (ROS/RNS-
related) or C > T (deamination-related) alterations and 23
GCs (> 50%) had an excess of both mutations (Fisher’s
exact test P-value < 0.01), establishing these two muta-
tional classes as the most significant single-nucleotide
alterations in GC. These patterns were independent of his-
tological subtype (intestinal, diffuse and mixed-type) and
MSI status (the excess is also seen in all but one non-MSI
tumor). Moreover, the frequencies of C > T and C > A
mutations were significantly different in GCs with active
H. pylori infection compared to those lacking active infec-
tion (Wilcoxon rank sum test P-value < 0.006 and 0.06,
respectively; Figure 3c). Overall, these results support the
widespread role of ROS/RNS-associated C > A and deami-
nation-associated C > T mutations in gastric cancer and
are suggestive of their link to H. pylori infection.
A strong signature for transcriptional-coupled repair has
been described before in other cancers [2,4] and our analy-
sis also confirmed this in GC, in that poorly transcribed
regions of the genome were associated with significantly
more mutations (Figure S8 and Note 8 in Additional file
1). However, in contrast with earlier reports, we did not
see a significant bias for mutations in the transcribed ver-
sus non-transcribed strand in most mutational classes
(except for T > G, P-value < 0.05, c2 test; Figure S8 in
Additional file 1). The absence of this latter pattern may
be a consequence of the higher mutational burden from
mutagens that also act in a transcription-coupled fashion
(for example, AID [16]).
Impact of mutational signatures on genes in GC
The overall impact of the mutational signatures identified
here on gastric tumorigenesis is a complex question influ-
enced by several factors, including the nature of muta-
tions, the function of genes that are frequently impacted
as well as genetic background and selection processes. We
aimed to provide an initial assessment using two
approaches: (i) by characterizing the proportion of genes
affected by various mutational classes; and (ii) by identify-
ing recurrently mutated genes in subtypes of GC defined
by mutational processes.
Overall, a majority of mutated genes in NGCII082 were
due to SNVs (77%) while CNVs and SVs played a domi-
nant role in NGCII092 (82%) (Table 1). In total, we identi-
fied 107 SVs that affected genes by truncation, fusion,
deletion, tandem duplication or rearrangements within the
gene body. Ninety-six (90%) of these were identified in the
CIN phenotype exhibiting tumor NGCII092, illustrating
the genic burden from this mutational process. In contrast,
small insertions and deletions (indels) were seen in few
genes, even in the tumor with MSI phenotype (despite
indels being roughly as common as SNVs genome-wide;
Table 1), though their ability to cause frameshifts is likely
to impact gene function more often than SNVs. Among
SNVs, even though the deamination-related C > T signa-
ture is only seen in a small fraction of the genome, it plays
a larger role in GC due to its targeted impact on genes.
More than 48% of the non-synonymous mutations seen
(48% in NGCII092 and 59% in NGCII082) in the two
tumors were due to C > T mutations, compared to less
than 19% for C > A mutations (Table 1). Among recur-
rently mutated genes in GC (Table S7 in Additional file 1
and Table S9 in Additional file 3), non-synonymous muta-
tions in the tumor suppressor genes TP53 (mutated in
50% of samples) and PTEN (18% of samples), and onco-
genes PIK3CA (13%; 8% have PTEN and PIK3CA muta-
tions) and CTNNB1 (10%) were often in the form of C >
T mutations (29%). This was also seen in several novel
recurrently mutated genes such as AQP7, SPTA1 and
RP1L1 (mutated in > 10% of tumors; Table S7 in Addi-
tional file 1).
Pathway analysis of mutated genes revealed that the
two most enriched sets were b1-integrin mediated cell-
surface interactions and signaling events mediated by
class III histone deacetylases, a refinement of previous
analysis [7] (Table S10 in Additional file 4). Furthermore,
we identified genes implicated in RAC1 regulation to be
mutated in 83% of H. pylori positive samples (P-value
< 0.05 Fisher’s exact test). RAC1 is a member of the Rho
GTPase family known to play diverse oncogenic roles
[18], shown to regulate the H. pylori virulence factor
VacA, and known to promote vacuole formation in
epithelial cells [19]. Mutations in the RAC1 pathway
could thus simultaneously promote H. pylori infection as
well as gastric tumorigenesis.
Finally, to further characterize the impact of mutational
processes on genes in GC, we considered two specific
subtypes for identifying recurrently mutated genes, MSI-
positive GC and TP53-wild-type GC (Tables S11 and S13
in Additional file 1 and Table S12 in Additional file 5).
We used TP53-wild-type status as a surrogate marker for
tumors without the CI phenotype as TP53 is known to
suppress chromosomal instability [20]. In this class of
GCs, in addition to the tumor suppressor gene PTEN
and TTK that interact with TP53, we identified PAPPA, a
marker for pregnancies with aneuploid fetuses [21], as
being recurrently mutated (Table S13 in Additional file 1;
note that the average mutation rate for the whole-
genome sequencing (WGS) samples in an approximately
2 Mbp window surrounding PAPPA is similar to the
genome-wide rate, that is 5.3 versus 5.2 mutations/Mbp).
A screen of an additional 94 gastric cancer/normal pairs
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confirmed the frequency of PAPPA mutations as being 6%
among all GC samples (Table S12 in Additional file 5) and
20% among TP53 wild-type GCs (with mutations in key
functional domains; Figures S13 and S14 in Additional
file 1), highlighting it as a potential driver gene in this
subtype.
In MSI-positive GCs, ACVR2A, RPL22, LMAN1, and
STAU2 were observed to have recurrent single base thy-
mine deletions in poly(T) regions (Table S11 in Additional
file 1) and this was confirmed in a screen of an additional
94 gastric cancer/normal paired samples (9 MSI-positive;
Table S12 in Additional file 5 and Figure S9 and Note 9 in
Additional file 1). In total, ACVR2A was mutated in a
region of 8 thymines in 86% of MSI-positive GCs tumors,
RPL22 in a region of 8 thymines in 64%, LMAN1 in a
region of 9 thymines in 50% and STAU2 in a region of 8
thymines in 29%. Based on the average frequency of muta-
tions in homopolymer regions in the MSI-positive tumors
(4.5% of 8 thymine stretches (n = 778) and 4.8% of 9 thy-
mine stretches (n = 183), respectively, in exomic regions),
mutations in ACVR2A, RPL22 and LMAN1 were in signifi-
cant excess (Bonferroni-corrected P-value ≤ 0.0003, exact
binomial test). In each gene, all the deletions occurred in
the same homopolymer tract containing thymines, a pat-
tern linked to the MSI phenotype, and none of the MSI-
negative GC tumors carried these mutations. In contrast,
mutations in the recently reported MSI-associated putative
driver gene ARID1A were not restricted to deletions or
MSI-positive tumors [7]. Interestingly, ACVR2A (encoding
a TGF-b super-family differentiation factor) has been
described to be recurrently mutated in MSI-positive color-
ectal cancer [22]. Also, the frequency of mutations seen
here is comparable to the previously reported frequency
in MSI-positive colorectal cancer [23,24] and emphasizes
the importance of ACVR2A and TGF-b signaling in MSI-
positive GC, while unraveling the oncogenic roles of
RPL22 and LMAN1 requires further investigation.
Discussion
Until long read sequencing of several kilo-base pairs is
routine, the combination of SR and long fragment mate-
pair sequencing remains the most powerful approach to
comprehensively capture micro- and macro-scale altera-
tions in the cancer genome. The combination of SR and
DNA-PET sequencing in this study thus provides the
first comprehensive assessment of somatic alterations in
GC. In particular, our results highlight the importance
of whole-genome analysis for reconstructing the lineage
of complex somatic structural variants and characteriz-
ing mutational process and their genomic impact in
cancer. For example, while point mutations in the KRAS
gene have been well characterized, our whole-genome
analysis enabled the first detailed reconstruction of
amplification in the KRAS locus (a common event in
GC) and a concomitant deletion of a proposed tumor
suppressor gene RASSF8.
The analysis of several exome-sequencing datasets in
earlier studies [6,7] was able to provide only a limited view
of mutational processes in GC. Whole-genome analysis
was essential for providing sufficient detail and statistics to
identify the features and relative impact of the various
mutational processes (for example, MSI, ROS/RNS and
CI). This is best exemplified by the identification of a
uniquely localized, deamination-linked mutational finger-
print whose significance would have been missed in an
exome-based study. We further characterized the impact
of this mutational process and identified the recurrently
mutated genes PAPPA, ACVR2A, RPL22, LMAN1,
and STAU2 in subtypes of GC defined by mutational
processes.
Conclusions
While computational tools for de novo cancer genome
assembly are limited, its utility is demonstrated by our
reconstruction of the H. pylori strain genome and assem-
bly-based characterization of SVs and fusion genes at the
base pair level. As sequencing costs continue to drop,
whole-genome sequencing and assembly of affected tissues
can serve as a tool for biomarker and pathogen discovery
in cancer and other diseases. Assembly tools need to be
refined to address the twin challenges of genomic amplifi-
cations and mixed cell populations and the availability of
whole-genome SR and DNA-PET data from the clinical
samples in this study should serve as a useful resource in
this effort.
Materials and methods
Patient samples and clinical information
Patient samples and clinical information on tissue and
blood samples were obtained from patients who had
undergone surgery for gastric cancer at the National
University Hospital, Singapore, and Tan Tock Seng Hospi-
tal, Singapore. Informed consent was obtained from all
subjects and the study was approved by the Institutional
Review Board of the National University of Singapore
(reference code 05-145) as well as the National Healthcare
Group Domain Specific Review Board (reference code
2005/00440). Clinical information for the two patients
whose samples were analyzed by whole-genome sequen-
cing is provided in Table S1 in Additional file 1 and
additional information for the 94 gastric tumors used for
targeted screening is provided in Table S12 in Additional
file 5.
Library preparation and sequencing
For WGS sequencing, genomic DNA isolated from tumor
and blood samples was randomly fractionated using a
Roche Nebulizer following the manufacturer’s instructions
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(Madison, Wisconsin, USA). Fractionated DNA was then
end-repaired, A-tailed at the 3’ end, ligated with Illumina
paired end adaptors, PCR amplified followed by gel-selec-
tion of a range of 400 to 600 bp fragments as templates
and sequenced by Illumina GA from both ends to obtain
76 or 101 bp reads at each end (Table S2 in Additional file
1). DNA-PET libraries were constructed as described else-
where [9] and were sequenced by the Applied Biosystems
SOLiD system (Carlsbad, California, USA, Table S3 in
Additional file 1). Exome sequencing was performed as
described earlier using SureSelect Human All Exon Kit v1
(Agilent Technologies, Santa Clara, California, USA) and
sequencing on two lanes of Illumina GA-IIx sequencer
using 76 bp paired-end reads [6].
Mapping and variant calling
Paired-end Illumina reads were mapped to the reference
human genome (UCSC hg18) using ELAND (Illumina
Inc.) and reads that failed pass-filter were removed from
further analysis. SNVs and indels were called for each
sample separately using SAMtools [25] (v0.1.7-6, SNP-
quality threshold = 20, consensus-quality threshold = 30)
(Table S4 in Additional file 1). Identical variant calls in
tumor and matched normal samples were used to iden-
tify germline variants. Variant calls unique to the tumor,
where the normal genotype called by SAMtools was dif-
ferent and where less than two reads of the variant geno-
type were seen in the normal sample, provided the list of
somatic variants. Illumina reads from exome sequencing
were analyzed using this pipeline after BWA [26] map-
ping (Table S8 in Additional file 1). As a control, we
noted that germline SNV frequencies were nearly identi-
cal across all exomes from WGS and exome sequencing
datasets (Figure S7 in Additional file 1). Somatic SNV
frequencies and neighborhoods were compared to germ-
line frequencies to assess enrichment. A neighborhood of
up to 2 bp surrounding an SNV was used to identify
enriched motifs. Somatic indel calls were required to be
supported by at least 20% of the reads, by reads on both
strands, with a minimum of 10 reads overlapping the
position in the tumor and no indel calls in the normal
sample. Somatic SNVs and indels in protein-coding
regions and introns were confirmed by Sanger sequen-
cing to have a high validation rate (83 SNVs, validation
rate = 90%; 72 indels, validation rate = 96%). SNV neigh-
borhood analysis was done by extracting 5 bp sequences
upstream and downstream of mutations. Germline and
somatic copy number variants were identified using the
program RDXplorer [27] with default parameters.
DNA-PET tags were mapped individually to the refer-
ence human genome (UCSC hg18) in color space allowing
two color code mismatches per tag by the SOLiD System
Analysis Pipeline Tool Corona Lite (Applied Biosystems
Inc.). Contigs of the reference sequence with unresolved
location (random_chr) and alternative MHC haplotypes
were excluded from the reference for mapping. Individu-
ally mapped tags were paired by Corona Lite. In cases
where one or both tags had multiple mapping locations, a
process termed ‘rescuing’ favored the creation of concor-
dant PETs (both tags are on the same chromosome, same
strand, same orientation, correct 5’ ® 3’ order and in the
expected distance to each other).
SVs, based on clusters of non-concordant PETs, were
called using the GIS DNA-PET pipeline [9] with refined
quality control criteria: (i) PET clusters of size < 6 were
excluded; (ii) the regions to which the 5’ and 3’ tags of
a cluster mapped had to be at least 1 kbp in size each;
(iii) PET clusters that had a supercluster (connected
component of overlapping clusters [9]) size > 100
required a higher cluster size of 10; and (iv) PET clus-
ters with high sequence similarity between the two
fused regions (BLAST score > 2,000 for 20 kbp windows
around the predicted break points) were excluded. To
distinguish between germline and somatic SVs, paired
normal and tumor samples were compared as described
previously [9]. Further filtering of known germline SVs
and PCR validation are described in Note 1 in Addi-
tional file 1.
Cancer genome assembly
Contig assembly, scaffolding and gap-filling of the Illu-
mina sequencing data were done using the assembler
SOAPdenovo [28]. DNA-PET reads were mapped to the
SOAPdenovo assembly with Bowtie [29] and the result-
ing linking information was used to produce larger scaf-
folds based on the optimal scaffolder Opera [30].
Scaffolds and contigs were refined further with the gap-
filling module in SOAPdenovo, employed for bridging
scaffold gaps, where feasible. Using the SR reads alone,
we obtained 12 kb scaffold N50 for both tumors. The
DNA-PET reads allowed for improvement of assembly
connectivity to a N50 of 65 kb and 41 kb for NGCII082
and NGCII092, respectively. Assemblies were compared
to the reference human genome (UCSC hg18) using the
MUMmer package [31] and alignments longer than 1
kbp were used to identify deletions and insertions larger
than 20 bp. Overall, 12,861 deletions and 143 insertions
were found in NGCII082 and 9,274 deletions and 108
insertions in NGCII092 of which 3 events > 2 kbp
missed by DNA-PET analysis were identified in each
sample. Fusion genes were validated and breakpoints
were confirmed by using the gap-filling module in
SOAPdenovo to bridge scaffolds constructed around the
breakpoint. Sequences missing in the reference human
genome were identified based on the criteria that they
should be > 500 bp long and have no match to the
reference genome with > 90% identity. Reads were
mapped to the novel sequences using Bowtie to identify
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regions with no read coverage in the middle of a scaf-
fold that could indicate a potential mis-assembly.
Analysis of microbial sequences
Reads with a putative microbial or viral origin were identi-
fied by mapping reads with no mapping to the human
genome, to a database of complete bacterial and viral gen-
omes in NCBI (using Bowtie [29]). Matches were filtered
for low-complexity sequences (more than three matches
of any 5-mer) and the remaining reads were used to esti-
mate the abundance for each species (pooling reads
mapped to different strains of a species). Each species was
checked for multiple distinct read matches to its genome
(> 4 distinct regions, where the genome was segmented in
1 kbp windows) and the presence of unique read matches
(using the unique option in Bowtie). The small fraction of
reads of putative bacterial origin in the matched blood
samples (possibly reagent contamination) were used as
control and read matches to the corresponding species
were excluded in determining the tumor associated micro-
biome. Concentration of H. pylori cells in relation to
tumor cells was estimated based on the assumption of
uniform coverage of both cell types, where coverage = k ×
Number of cells × Size of genome, for a constant k and
the populations are assumed to be clonal.
Functional annotation of SNVs and indels
For all samples, SNV and indel calls were annotated using
the SeattleSeq server [32] and SIFT [33], respectively. Path-
way analyses were performed based on non-synonymous
SNVs and indels using the Pathway Interaction Database
[34] (sample pfg005T from Wang et al. [7] was excluded as
it only had four somatic mutations).
Data access
Sequencing data for this publication have been deposited
in NCBI’s Gene Expression Omnibus [35] and is accessible
through GEO Series accession number GSE30833.
Additional material
Additional file 1: Supplementary Methods, Tables and Figures.
Additional file 2: Table S6. Details of somatic SVs identified by
DNA-PET in gastric tumors NGCII082 and NGCII092.
Additional file 6: Table S14. Enriched bases and motifs in the
neighbourhood of C > A mutations.
Additional file 3: Table S9. Genes recurrently mutated by non-
synonymous SNVs or indels in four or more patients out of 40 GC
exomes.
Additional file 4: Table S10. Enriched functions and pathways in
Gastric Cancer.
Additional file 5: Table S12. Screen for recurrent mutations in 94
GC tumor/normal pairs by Sanger sequencing.
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